BioMate is building a new generation of medicines for immune-mediated disease — autoimmune, chronic infection, and immuno-oncology. We identify targets from human biology and design cyclic-peptide medicines, on an AI platform of our own: self-hosted models, a closed loop that gets stronger with every experiment, and honest, private validation. The same platform is open to any team doing hard science.
Plenty of products wire existing tools together. BioMate is different in kind: it brings proprietary techniques into one environment — a self-hosted model trained for scientific work, an advanced closed-loop system with a verifiable reward, and reproducible execution across 4,000+ catalog workflows in 36 biomedical domains.
It is the foundation we build on, the one we always use to do what we need — and it is open to any team doing hard science.
We run our own drug development on that platform. First we identify the target — the choice that most often decides whether a drug works — from human genetics and patient data. Then we design the molecule: an AI-designed cyclic peptide, optimized in silico against every constraint and proven in the wet lab, round after round.
Our focus is immune-mediated disease — autoimmune, chronic infection, and immuno-oncology. Pre-clinical today.
BioMate was founded in late 2025 by a team with deep roots in biomedical informatics and NLP. The founding insight was simple: the bottleneck in computational life science is not capability — it is access. The tools exist. The methods are published. What is missing is a platform that makes them usable by the scientists who need them, without requiring a computational specialist at every step.
We built the platform the way the science demanded: evidence-grounded, auditable, and broad enough to cover the full span of computationally demanding biomedical work — from genomics and structural biology to drug discovery, clinical pharmacology, and regulatory documentation. Where we go deepest is immune-mediated disorders: nominating and de-risking targets, designing peptide and macrocycle candidates, and closing the design–make–test loop with wet-lab feedback.
Every result on BioMate is defensible — by design, not by documentation.
Today BioMate is in production with pilot teams across pharma, biotech, CROs, and academic medical centers — 4,000+ indexed workflows, 36 domains, and a quality framework that regulatory reviewers and journal editors can inspect at the parameter level.
| Founded | Late 2025 |
|---|---|
| Headquarters | Houston, Texas — Texas Medical Center |
| Platform | AI platform integrating our own model, an advanced closed-loop system, and 4,000+ catalog workflows across 36 biomedical domains |
| Focus program (on the platform) | Our own drug development: cyclic-peptide therapeutics for immune-mediated disease (target ID · molecular design · closed-loop). Pre-clinical. |
| Key integrated tools | GATK, DeepVariant, STAR, salmon, Seurat, AlphaFold 2/3, CryoSPARC, AutoDock Vina, GROMACS, DESeq2, MaxQuant, QIIME 2 |
| Pricing | Free — no card required; Pro $49/mo; Team $199/mo; Enterprise — contact sales |
| Compliance | HIPAA-compliant; BAA available; private VPC deployment option |
| Data policy | Your data is never used to train shared AI models; tenant-isolated workspace |
Not aspirational statements. The constraints we apply when deciding what to build, what to charge, and what to refuse.
BioMate spans the full breadth of modern life science research — from raw sequencing data to IND-ready documents. Each domain draws on the community's gold-standard open-source tools, accessible through a plain-English request.